nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2019-3-129-136nnp-1187Research ArticleREVIEWSОБЗОРЫAdvances in neurometabolic therapyДостижения нейрометаболической терапииЗахаровВ. В.ZakharovV. V.

Кафедра нервных болезней и нейрохирургии,

119021, Москва, ул. Россолимо, 11, стр. 1

Department of Nervous System Diseases and Neurosurgery,

11, Rossolimo St., Build 1, Moscow 119021

ВахнинаН. В.VakhninaN. V.

Кафедра нервных болезней и нейрохирургии,

119021, Москва, ул. Россолимо, 11, стр. 1

Department of Nervous System Diseases and Neurosurgery,

11, Rossolimo St., Build 1, Moscow 119021

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет)» Минздрава РоссииРоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation201901112019113129136Copyright © Zakharov V.V., Vakhnina N.V., 20192019Захаров В.В., Вахнина Н.В.Zakharov V.V., Vakhnina N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1187

Actovegin is a calf blood extract that contains more than 200 biologically active compounds. Experiments have shown that Actovegin reduces the neurotoxic effect of amyloid, neutralizes reactive oxygen species, and normalizes the endothelial function of small vessels. The drug has not been shown to stimulate tumor growth in the neuroblastoma model. Clinical experience with Actovegin suggests that the drug has an undoubted efficacy in treating moderate vascular cognitive impairment and chronic distal symmetric diabetic polyneuropathy and that it is used as additional therapy for primary degenerative and vascular dementia. The clinical efficacy of Actovegin in chronic obliterating diseases of the lowerlimb arteries is being actively studied now.

Актовегин – производное крови телят, которое содержит более 200 биологически активных соединений. В экспериментальных условиях показано, что Актовегин уменьшает нейротоксический эффект амилоида, нейтрализует активные формы кислорода, нормализует эндотелиальную функцию сосудов небольшого калибра. На модели нейробластомы показано, что препарат не стимулирует опухолевый рост. Клинический опыт использования Актовегина свидетельствует о его несомненной эффективности при умеренных когнитивных нарушениях сосудистого генеза и при хронической симметричной дистальной диабетической полиневропатии, а также в качестве дополнительной терапии деменции первично-дегенеративной и сосудистой природы. В настоящее время активно изучается клиническая эффективность Актовегина при хронических облитерирующих заболеваниях артерий нижних конечностей.

Актовегинсосудистые когнитивные нарушенияполиневропатияActoveginvascular cognitive impairmentpolyneuropathyПубликация статьи поддержана ООО «Такеда Фармасьютикалс».ReferencesBuchmayer F, Pleiner J, Elminger MW, et al. Actovegin®: a biological drug for more than 5 decades. Wien Med Wochenschr. 2011;161 (3-4):80-8. doi: 10.1007/s10354-011-0865-yBuchmayer F, Pleiner J, Elminger MW, et al. Actovegin®: a biological drug for more than 5 decades. Wien Med Wochenschr. 2011;161 (3-4):80-8. doi: 10.1007/s10354-011-0865-yMachicao F, Muresanu DF, Hundsberger H, Pflü ger M, Guekht A. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci. 2012;322(1):222-7. doi: 10.1016/j.jns.2012.07.069Machicao F, Muresanu DF, Hundsberger H, Pflü ger M, Guekht A. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci. 2012;322(1):222-7. doi: 10.1016/j.jns.2012.07.069Herrschaft H, Kunze U, Gleim F. The action of Actovegin on cerebral blood flow and cerebral metabolism in man. Med Welt. 1977;28:339-45.Herrschaft H, Kunze U, Gleim F. The action of Actovegin on cerebral blood flow and cerebral metabolism in man. Med Welt. 1977;28:339-45.Jager KH, Leybold K, Mittenzwei H, et al. The promotional of cell respiration by a blood extract. Arzneimittel-Forschung / Drug Res. 1965; 15:750-4.Jager KH, Leybold K, Mittenzwei H, et al. The promotional of cell respiration by a blood extract. Arzneimittel-Forschung / Drug Res. 1965; 15:750-4.De Groot, Brecht M, Machicao F. Evidence for a factor protective against hypoxic liver parenchymal cell injury in a protein-free blood extract. Res Comm Chem Path Pharm. 1990; 68:125-8.De Groot, Brecht M, Machicao F. Evidence for a factor protective against hypoxic liver parenchymal cell injury in a protein-free blood extract. Res Comm Chem Path Pharm. 1990; 68:125-8.Reichel H, Weiss C, Leichtweiss HP. The effects of a blood extract on the oxygen uptake of isolated artificially perfused kidneys and skeletal muscles in rats. Arzneim-Forsch. 1965;15(756):757.Reichel H, Weiss C, Leichtweiss HP. The effects of a blood extract on the oxygen uptake of isolated artificially perfused kidneys and skeletal muscles in rats. Arzneim-Forsch. 1965;15(756):757.Kuninaka T, Senga Y, Senga H, Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J Cell Physiol. 1991;146(1):148-55. doi: 10.1002/jcp.1041460119Kuninaka T, Senga Y, Senga H, Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J Cell Physiol. 1991;146(1):148-55. doi: 10.1002/jcp.1041460119Bachmann W, Forster H, Mehnert H. Experimental studies in animals on the effect of a protein-free blood extract on the metabolism of glucose. Arzneimittel-Forschung / Drug Res. 1968;18:1023-7.Bachmann W, Forster H, Mehnert H. Experimental studies in animals on the effect of a protein-free blood extract on the metabolism of glucose. Arzneimittel-Forschung / Drug Res. 1968;18:1023-7.Parade D, Biro G, Ketti H, et al. Studies on the insulin-like action of a low molecularweight blood extract on the glucose metabolism of isolated isolated tissue of the rat in vitro. Arzneimittel-Forschung / Drug Res. 1968;18: 1019-21.Parade D, Biro G, Ketti H, et al. Studies on the insulin-like action of a low molecularweight blood extract on the glucose metabolism of isolated isolated tissue of the rat in vitro. Arzneimittel-Forschung / Drug Res. 1968;18: 1019-21.Mohnike G, Lippmann HG, Dieckmann I, et al. Zur Wirkung eines Extraktes aus Kalberblut im Stoffwechsel der Glucose. Arzneimittel-Forschung / Drug Res. 1968;18:1021.Mohnike G, Lippmann HG, Dieckmann I, et al. Zur Wirkung eines Extraktes aus Kalberblut im Stoffwechsel der Glucose. Arzneimittel-Forschung / Drug Res. 1968;18:1021.Machicao F, Mü hlbacher Ch, Haring HU. Inositol phospho-ooligosaccharides from a dialysate [Actovegin] obtained from blood mimic the effect on lipogenesis glucose transport and lipolysis in rat adipocytes. Aktuelle Endokrinologie und Stoffwechsel. 1989;10(2):111.Machicao F, Mü hlbacher Ch, Haring HU. Inositol phospho-ooligosaccharides from a dialysate [Actovegin] obtained from blood mimic the effect on lipogenesis glucose transport and lipolysis in rat adipocytes. Aktuelle Endokrinologie und Stoffwechsel. 1989;10(2):111.Machicao F, Sixt B, Seffer E, et al. Adipocytes release inositol phosphate oligosaccharides with insulin like activity similarly as found in hemodialysate. In: IV International Symposium on Insulin Receptor and Insulin Action, Verona, Italy; 1990. P. 124.Machicao F, Sixt B, Seffer E, et al. Adipocytes release inositol phosphate oligosaccharides with insulin like activity similarly as found in hemodialysate. In: IV International Symposium on Insulin Receptor and Insulin Action, Verona, Italy; 1990. P. 124.Machicao F, Mushack J, Seffer E, et al. Mannose, glucosamine and inositol monophosphate inhibit the effects of insulin on lipogenesis. Further evidence for a role for inositol phosphate-oligosaccharides in insulin action. Biochem J. 1990;266:909-16.Machicao F, Mushack J, Seffer E, et al. Mannose, glucosamine and inositol monophosphate inhibit the effects of insulin on lipogenesis. Further evidence for a role for inositol phosphate-oligosaccharides in insulin action. Biochem J. 1990;266:909-16.Jaacob S, Dietze GJ, Machicao F, et al. Improvement of glucose metabolism in patients with type II diabetes after treatment with hemodialysate. Arzneimittelforschung. 1996;(3): 269-72.Jaacob S, Dietze GJ, Machicao F, et al. Improvement of glucose metabolism in patients with type II diabetes after treatment with hemodialysate. Arzneimittelforschung. 1996;(3): 269-72.Dieckmann A, Kriebel M, Andriambeloson E, et al. Treatment with Actovegin improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation. Exp Clin Endocrinol Diabetes. 2011;120(3):132-8.Dieckmann A, Kriebel M, Andriambeloson E, et al. Treatment with Actovegin improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation. Exp Clin Endocrinol Diabetes. 2011;120(3):132-8.Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro. Neuromolecular Med. 2011; 13(4):266-74. doi: 10.1007/s12017-011-8157-7Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro. Neuromolecular Med. 2011; 13(4):266-74. doi: 10.1007/s12017-011-8157-7Fedorovich AA. Non-invasive evaluation of vasomotor and metabolic functions of microvascular endothelium in human skin. Microvasc Res. 2012;84:86-93. doi: 10.1016/j.mvr.2012.03.011Fedorovich AA. Non-invasive evaluation of vasomotor and metabolic functions of microvascular endothelium in human skin. Microvasc Res. 2012;84:86-93. doi: 10.1016/j.mvr.2012.03.011Meilin S, Machicao F, Elmlinger M. Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia. J Cell Mol Med. 2014;18(8): 1623-30. doi: 10.1111/jcmm.12297Meilin S, Machicao F, Elmlinger M. Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia. J Cell Mol Med. 2014;18(8): 1623-30. doi: 10.1111/jcmm.12297Herrmann WM, Bohn-Olszewsky WJ, Kuntz G. Actovegin infusion treatment in patients with primarily degenerative dementia of the Alzheimer type and multi-infarct dementia. Zeitschrift fü r Geriatrie. 1992;5:46-55. 20. Kanowski S, Kinzler E, Lehmann E, et al. Confirmed Clinical Efficacy of Actoveginmin Elderly Patients with Organic Brain Syndrome. Pharmacopsychiat. 1995;28:125-33. doi: 10.1055/s-2007-979604Herrmann WM, Bohn-Olszewsky WJ, Kuntz G. Actovegin infusion treatment in patients with primarily degenerative dementia of the Alzheimer type and multi-infarct dementia. Zeitschrift fü r Geriatrie. 1992;5:46-55. 20. Kanowski S, Kinzler E, Lehmann E, et al. Confirmed Clinical Efficacy of Actoveginmin Elderly Patients with Organic Brain Syndrome. Pharmacopsychiat. 1995;28:125-33. doi: 10.1055/s-2007-979604Guekht A, Skoog I, Edmundson S, et al. ARTEMIDA trial (A Randomized Trial of Efficacy, 12 Months International DoubleBlind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017;48:1262-70. doi: 10.1161/STROKEAHA.116.014321Guekht A, Skoog I, Edmundson S, et al. ARTEMIDA trial (A Randomized Trial of Efficacy, 12 Months International DoubleBlind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017;48:1262-70. doi: 10.1161/STROKEAHA.116.014321Яннсен В, Брукнер ГВ. Лечение хронической цереброваскулярной недостаточности с использованием драже актовегин форте. Русский медицинский журнал. 2002; 10(12):1-4Yannsen V, Brukner GV. Treatment of chronic cerebrovascular insufficiency using actotegin forte pills. Russkii Meditsinskii Zhurnal. 2002;10(12):1-4 (In Russ.).Oswald WD, Steiger W, Oswald B, Kuntz G. Die Verbesserung fluider kognitiver leistungen als indikator fuer die klinische Wirksamkeit einer nootropen Substanz. Eine Placebo-kontrollierte Doppelblind-Studie mit Actovegin). Zeitschrifft fur Gerontopsychologie und Psychiatrie. 1991;4:209-20.Oswald WD, Steiger W, Oswald B, Kuntz G. Die Verbesserung fluider kognitiver leistungen als indikator fuer die klinische Wirksamkeit einer nootropen Substanz. Eine Placebo-kontrollierte Doppelblind-Studie mit Actovegin). Zeitschrifft fur Gerontopsychologie und Psychiatrie. 1991;4:209-20.Saletu B, Gruenberg J, Linzmayer L, et al. EEG Brain Mapping and Psychometry in AgeAssociated Memory Impairment after Acute and 2-Week Infusions with the Gemoderivative Actovegin: Double-Blind, Placebo-Controlled Trials. Neuropsychobiology. 1990;91(24):135-48. doi: 10.1159/000119476Saletu B, Gruenberg J, Linzmayer L, et al. EEG Brain Mapping and Psychometry in AgeAssociated Memory Impairment after Acute and 2-Week Infusions with the Gemoderivative Actovegin: Double-Blind, Placebo-Controlled Trials. Neuropsychobiology. 1990;91(24):135-48. doi: 10.1159/000119476Saletu B, Griinberger I, Linzmayer L, Stahr H. Zur Funktionsverbesserung des alternden Gehirns: Plazebokontrollierte PharmaltoEEG und psychometrische Studien mit einem stoffwechselaktiven Hamoderivat (Actovegin). Gerontol. 1984;17:271-9.Saletu B, Griinberger I, Linzmayer L, Stahr H. Zur Funktionsverbesserung des alternden Gehirns: Plazebokontrollierte PharmaltoEEG und psychometrische Studien mit einem stoffwechselaktiven Hamoderivat (Actovegin). Gerontol. 1984;17:271-9.Semiitsch HV, Anderer P, Saletu B, Hochmayer I. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment. Neuropsychobiology. 1990-1991; 24:49-56. doi: 10.1159/000119042Semiitsch HV, Anderer P, Saletu B, Hochmayer I. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment. Neuropsychobiology. 1990-1991; 24:49-56. doi: 10.1159/000119042Федорович АА, Соболева ГН. Коррекция когнитивных нарушений Актовегином у больных артериальной гипертензией и ишемической болезнью сердца. Эффективная фармакотерапия. 2015;23:42-51Fedorovich AA, Soboleva GN. Correction of cognitive impairment with Actovegin in patients with arterial hypertension and coronary heart disease. Effektivnaya Farmakoterapiya. 2015; 23:42-51 (In Russ.).Михайлова НМ, Селезнева НД, Калын ЯБ и др. Эффективность лечения актовегином больных пожилого возраста с синдромом мягкого когнитивного снижения сосудистого генеза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013; 7(2):68-75.Mikhailova NM, Selezneva ND, Kalyn YaB, et al. Efficacy of treatment with aktovegin elderly patients with mild cognitive decline syndrome of vascular genesis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013; 7(2):68-75 (In Russ.).Остроумова ОД. Коррекция когнитивных нарушений Актовегином у больных гипертонической болезнью. Медицинский алфавит. 2012;(4):4-8.Ostroumova OD. Correction of cognitive impairment with Actovegin in patients with essential hypertension. Meditsinskii Alfavit. 2012;(4):4-8 (In Russ.).Захаров ВВ, Сосина ВБ. Возможности антигипоксантов в лечении умеренных когнитивных нарушений у больных сахарным диабетом. Лечащий врач. 2010;(3):87-91.Zakharov VV, Sosina VB. Possibilities of antihypoxic drugs in the treatment of moderate cognitive impairment in patients with diabetes mellitus. Lechashchii Vrach. 2010;(3):87-91 (In Russ.).Ziegler D, Movsesyan L, Mankovsky B, et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32(8):1479-84. doi: 10.2337/dc09- 0545Ziegler D, Movsesyan L, Mankovsky B, et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32(8):1479-84. doi: 10.2337/dc09- 0545Моргоева ФЭ, Аметов АС, Строков ИА. Диабетическая энцефалопатия и полиневропатия: терапевтические возможности Актовегина. Русский медицинский журнал. 2005;(6):302-6.Morgoeva FE, Ametov AS, Strokov IA. Diabetic encephalopathy and polyneuropathy: Actovegin's therapeutic potential. Russkii Meditsinskii Zhurnal. 2005;(6): 302-6 (In Russ.).Horsch S, Claeys L, Diehm C, et al. [Assessment of the clinical effectiveness of actihaemyl in Fontaine stage IIb intermittent claudication]. Vasa Suppl. 1992;37:64-5.Horsch S, Claeys L, Diehm C, et al. [Assessment of the clinical effectiveness of actihaemyl in Fontaine stage IIb intermittent claudication]. Vasa Suppl. 1992;37:64-5.Angelkort B, Ruhlmann KU, de la Haye R, et al. Influence of deproteinized hemodialysate on rest pain and walking distance in the presence of peripheral chronic arterial occlusive disease. Angiology. 1992;43:47-58. doi: 10.1177/000331979204300106Angelkort B, Ruhlmann KU, de la Haye R, et al. Influence of deproteinized hemodialysate on rest pain and walking distance in the presence of peripheral chronic arterial occlusive disease. Angiology. 1992;43:47-58. doi: 10.1177/000331979204300106Учкин ИГ, Зудин АМ, Багдасарян АГ, Федорович АА. Влияние фармакотерапии хронических облитерирующих заболеваний артерий нижних конечностей на состояние микроциркуляторного русла. Ангиология и сосудистая хирургия. 2014;20(2):27-36.Uchkin IG, Zudin AM, Bagdasaryan AG, Fedorovich AA. The effect of pharmacotherapy of chronic obliterating diseases of lower limb arteries on the state of the microvasculature. Angiologiya i Sosudistaya Khirurgiya. 2014; 20(2):27-36 (In Russ.).Stein R, Seuser J. Local use of Actovegin ampoule solution in crural ulcer. Med Welt. 1986;37:173-6.Stein R, Seuser J. Local use of Actovegin ampoule solution in crural ulcer. Med Welt. 1986;37:173-6.Учкин ИГ, Мосесов АГ, Цырульников АА. Актовегин как компонент комплексной терапии осложненных форм хронической венозной недостаточности нижних конечностей. Русский медицинский журнал. 2007; 12(15):981-5.Uchkin IG, Mosesov AG, Tsyrul'nikov AA. Actovegin as a component of the complex therapy of complicated forms of chronic venous insufficiency of the lower extremities. Russkii Meditsinskii Zhurnal. 2007; 12(15):981-5 (In Russ.).Хисматов РР, Трухова ВВ, Макарова НН, Гусева СЛ. Актовегин в лечении трофических язв нижних конечностей венозной этиологии. Русский медицинский журнал. 2008;30(16):2022-4.Khismatov RR, Trukhova VV, Makarova NN, Guseva SL. Actovegin in the treatment of trophic ulcers of the lower extremities of venous etiology. Russkii Meditsinskii Zhurnal. 2008;30(16):2022-4 (In Russ.).https://clinicaltrials.gov/ct2/show/NCT03469349?term=Actovegin&rank=1https://clinicaltrials.gov/ct2/show/NCT03469349?term=Actovegin&rank=1Sondergard SD, Dela F, Helge JW, Larsen S. Actovegin, a nonprohibited drug increases oxidative capacity in human skeletal muscle. Eur J Sport Sci. 2016;16:801-7. doi: 10.1080/17461391.2015.1130750Sondergard SD, Dela F, Helge JW, Larsen S. Actovegin, a nonprohibited drug increases oxidative capacity in human skeletal muscle. Eur J Sport Sci. 2016;16:801-7. doi: 10.1080/17461391.2015.1130750Lee P, Rattenberry A, Connelly S, Nokes L. Our experience on Actovegin, is it cutting edge? Int J Sports Med. 2011;32:237-41. doi: 10.1055/s-0030-1269862Lee P, Rattenberry A, Connelly S, Nokes L. Our experience on Actovegin, is it cutting edge? Int J Sports Med. 2011;32:237-41. doi: 10.1055/s-0030-1269862WADA. Список запрещенных препаратов (2017 г.). Доступно по ссылке: https://www.wadaama.org/en/media/news/201 6-09/wadapublishes-2017-prohibited-list [WADA, List of prohibited drugs (2017). Available by reference: https://www.wadaama.org/en/media/news/201 6-09/wadapublishes-2017-prohibited-list].WADA. Список запрещенных препаратов (2017 г.). Доступно по ссылке: https://www.wadaama.org/en/media/news/201 6-09/wadapublishes-2017-prohibited-list [WADA, List of prohibited drugs (2017). Available by reference: https://www.wadaama.org/en/media/news/201 6-09/wadapublishes-2017-prohibited-list].Reichl FY, Holdt LM, Teupser D, et al. Comprehensive analytics of Actovegin® and its effect on muscle cells. Int J Sports Med. 2017; 38:809-18. doi: 10.1055/s-0043-115738Reichl FY, Holdt LM, Teupser D, et al. Comprehensive analytics of Actovegin® and its effect on muscle cells. Int J Sports Med. 2017; 38:809-18. doi: 10.1055/s-0043-115738Pforringer W, Pfister A, Kuntz G. The treatment of Achilles paratendinitis: results of a double-blind, placebo-controlled study with a deproteinized hemodialysate. Clin J Sport Med. 1994;4:92-9. doi: 10.1097/00042752-199404000-00005Pforringer W, Pfister A, Kuntz G. The treatment of Achilles paratendinitis: results of a double-blind, placebo-controlled study with a deproteinized hemodialysate. Clin J Sport Med. 1994;4:92-9. doi: 10.1097/00042752-199404000-00005Бойченко МН, Волчкова ЕВ, Пак СГ. Биопрепараты и прионные болезни, возможна ли этиологическая связь? Фарматека. 2012;s3-12:47-54.Boichenko MN, Volchkova EV, Pak SG. Biopreparations and prion diseases, is etiological connection possible? Farmateka. 2012;s3-12:47-54 (In Russ.).Винокуров МГ, Юринская ММ, Князев АВ, Асташкин ЕИ. Влияние гемодеривата крови телят на жизнеспособность, апоптоз и некроз клеток нейробластомы человека SK-N-SH. Экспериментальная и клиническая фармакология. 2017;80(3):31-5.Vinokurov MG, Yurinskaya MM, Knyazev AV, Astashkin EI. Effect of calf blood hemoderivate on viability, apoptosis and necrosis of human neuroblastoma cells SK-N-SH. Eksperimental'naya i Klinicheskaya Farmakologiya. 2017; 80(3):31-5 (In Russ.).

The authors declare that there are no conflicts of interest present.